SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Signorini, G.P.
Right arrow Articles by Maraglino, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Signorini, G.P.
Right arrow Articles by Maraglino, G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Efficacy of Indobufen in the Treatment of Intermittent Claudication

G.P. Signorini

Geriatric Hospital, Padua, Italy

G. Salmistraro

Geriatric Hospital, Padua, Italy

G. Maraglino

Geriatric Hospital, Padua, Italy

The aim of this trial was to assess the activity of indobufen compared with placebo in peripheral occlusive arterial disease of the lower limbs of atheroscle rotic or diabetic origin. Fifty-two outpatients were admitted to the randomized, double-blind study and were given either an indobufen 200-mg tablet (28 sub jects) or placebo (24) for six months.

Painfree walking distance on a treadmill at a constant speed (4 km/h) and slope (10°) was assessed before and after three and six months' treatment. The painfree walking distance before treatment with indobufen or placebo averaged 153 ± 23.02 (mean ± SE) and 199 ± 30.58 (mean ± SE) meters respectively.

After six months' treatment with active drug or placebo, this parameter reached 610 ± 115.36 (p < 0.01) and 243 ± 32.49 (p > 0.05) meters respec tively. The difference between the two treatments was statistically significant in favor of indobufen (p < 0.01 Dunn's test).

Angiology, Vol. 39, No. 8, 742-746 (1988)
DOI: 10.1177/000331978803900806
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 ANGIOLOGYHome page
G. Castano, R. Mas, J. Roca, L. Fernandez, J. Illnait, J. C. Fernandez, E. Selman, and R. Mas
A Double-Blind, Placebo-Controlled Study of the Effects of Policosanol in Patients with Intermittent Claudication
Angiology, February 1, 1999; 50(2): 123 - 130.
[Abstract] [PDF]

Home page
 ANGIOLOGYHome page
E. Panchenko, A. Eshkeeva, A. Dobrovolsky, E. Titaeva, Ya. Podinovskaya, K.M.A. Hussain, Yu. Karpov, and E. Panchenko
Effects of Indobufen and Pentoxifylline on Walking Capacity and Hemostasis in Patients with Intermittent Claudication: Results of Six Months of Treatment
Angiology, March 1, 1997; 48(3): 247 - 254.
[Abstract] [PDF]

Home page
 ANGIOLOGYHome page
V. Coto, M. Cocozza, U. Oliviero, A. Lucariello, T. Picano, F. Coto, and L. Cacciatore
Clinical Efficacy of Picotamide in Long-Term Treatment of Intermittent Claudication
Angiology, October 1, 1989; 40(10): 880 - 885.
[Abstract] [PDF]


Advertisement